Gökhan KESER, Pamir ATAGÜNDÜZ, Mehmet SOY

Pathogenesis and treatment of cytokine storm in COVID-19

COVID-19 is a viral infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that killed a large number of patients around the world. A hyperinflammatory state resulting in a cytokine storm and adult respiratory distress syndrome seems to be the major cause of the death. Many mechanisms have been suggested in the pathogenesis of COVID-19 associated cytokine storm (COVID-CS). Insufficient viral clearance and persistence of a strong cytokine response despite inadequate antiviral immunity seem to be the main mechanisms underlying the pathogenesis. The diagnosis of COVID-19 is based on relatively constant clinical symptoms, clinical findings, laboratory tests, and imaging techniques, while the diagnosis of COVID-CS is a rather dynamic process, based on evolving or newly emerging findings during the clinical course. Management of COVID-19 consists of using antiviral agents to inhibit SARS-CoV-2 replication and treating potential complications including the cytokine storm together with general supportive measures. COVID-CS may be treated using appropriate immunosuppressive and immunomodulatory drugs that reduce the level of inappropriate systemic inflammation, which has the potential to cause organ damage. Currently corticosteroids, IL-6 blockers, or IL-1 blockers are most widely used for treating COVID-CS.

PDF

___

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF (2020). The proximal origin of SARS-CoV-2. Nature Medicine 26 (4): 450-452. doi: 10.1038/s41591-020-0820-9
Baghaei P, Dastan F, Marjani M, Moniri A, Abtahian Z et al. (2021). Combination therapy of IFNβ1 with lopinavir– ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. International Immunopharmacology 92: 107329. doi: 10.1016/j. intimp.2020.107329
Barrat FJ, Elkon KB, Fitzgerald KA (2016). Importance of nucleic acid recognition in inflammation and autoimmunity. Annual Review of Medicine 67 (1): 323-336. doi: 10.1146/annurevmed-052814-023338
Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH et al. (2020). Autoantibodies against type I IFNs in patients with lifethreatening COVID-19. Science 370 (6515): eabd4585. doi: 10.1126/science.abd4585
Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I et al. (2020). COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. Journal of the American College of Cardiology 75 (23): 2950-2973. doi: 10.1016/j.jacc.2020.04.031
Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ et al. (2020). Angiotensin‐converting enzyme 2 (ACE2), SARS‐ CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). The Journal of Pathology 251 (3): 228-248. doi: 10.1002/path.5471
Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-hunt M et al. (2020). Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology 159 (2): 481-491.e3. doi: 10.1053/j. gastro.2020.05.032
Campochiaro C, Della-torre E, Cavalli G, De Luca G, Ripa M et al. (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine 76: 43-49. doi: 10.1016/j. ejim.2020.05.021
Cantini F, Niccoli L, Nannini C, Matarrese D, Natale MED et al. (2020). Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study. Journal of Infection 81 (4): 647- 679. doi: 10.1016/j.jinf.2020.06.052
Cao W, Liu X, Bai T, Fan H, Hong K et al. (2020b). High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open Forum Infectious Diseases 7 (3). doi: 10.1093/ofid/ofaa102
Cao Y, Wei J, Zou L, Jiang T, Wang G et al. (2020a). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology 146 (1): 137-146. e3. doi: 10.1016/j.jaci.2020.05.019
Caricchio R, Gallucci M, Dass C, Zhang X, Gallucci S et al. (2020). Preliminary predictive criteria for COVID-19 cytokine storm. Annals of the Rheumatic Diseases 80 (1): 88-95. doi: 10.1136/ annrheumdis-2020-218323
Cavalli G, Larcher A, Tomelleri A, Campochiaro C, Della-torre E et al. (2021). Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. The Lancet Rheumatology 3 (4): e253-e261. doi: 10.1016/S2665-9913(21)00012-6
Chen Y, Liu Q, Guo D (2020). Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of Medical Virology 92 (4): 418-423. doi: 10.1002/jmv.25681
Cicco S, Cicco G, Racanelli V, Vacca A (2020). Neutrophil extracellular traps (NETs) and damage-associated molecular patterns (DAMPs): two potential targets for COVID-19 treatment. Mediators of Inflammation 2020: 1-25. doi: 10.1155/2020/7527953
Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V et al. (2020). Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms 8 (5): 695. doi: 10.3390/ microorganisms8050695
Colmenero I, Santonja C, Alonso‐riaño M, Noguera‐morel L, Hernández‐martín A et al. (2020). SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. British Journal of Dermatology 183 (4): 729- 737. doi: 10.1111/bjd.19327
Crow (2019). Type I interferons in host defence and inflammatory diseases. Lupus Science & Medicine 6 (1).
Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ et al. (2020). Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet 395 (10239): 1763-1770. doi: 10.1016/S0140-6736(20)31189-2
Dinarello CA, Van Der Meer JW (2013). Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology 25 (6): 469-484. doi: 10.1016/j.smim.2013.10.008
Favalli EG, Biggioggero M, Maioli G, Caporali R (2020). Baricitinib for COVID-19: a suitable treatment? The Lancet Infectious Diseases 20 (9): 1012-1013. doi: 10.1016/S1473- 3099(20)30262-0
Ferreira AC, Soares VC, De Azevedo-quintanilha IG, Dias SDSG, Fintelman-rodrigues N et al. (2021). SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes. Cell Death Discovery 7 (1). doi: 10.1038/s41420-021-00428-w
Fu B, Xu X, Wei H (2020). Why tocilizumab could be an effective treatment for severe COVID-19? Journal of Translational Medicine 18 (1). doi: 10.1186/s12967-020-02339-3
Gianfrancesco M, Hyrich KL, Al-adely S, Carmona L, Danila MI et al. (2020). Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases 79 (7): 859-866. doi: 10.1136/annrheumdis-2020-217871
Grolmusz VK, Bozsik A, Papp J, Patócs A (2021). Germline genetic variants of viral entry and innate immunity may influence susceptibility to SARS-CoV-2 infection: toward a polygenic risk score for risk stratification. Frontiers in Immunology 12. doi: 10.3389/fimmu.2021.653489
Guan W, Ni Z, Hu Y, Liang W, Ou C et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 382 (18): 1708-1720. doi: 10.1056/NEJMoa2002032
Herth FJ, Sakoulas G, Haddad F (2020). Use of intravenous immunoglobulin (Prevagen or Octagam) for the treatment of COVID-19: retrospective case series. Respiration 99 (12): 1145-1153. doi: 10.1159/000511376
Hoffmann M, Kleine-weber H, Schroeder S, Krüger N, Herrler T et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181 (2): 271-280.e8. doi: 10.1016/j. cell.2020.02.052
Horby P, Lim WS, Emberson J, Mafham M, Bell JL et al. (2021). Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine 384 (8): 693-704. doi: 10.1056/ NEJMoa2021436
Huang C, Wang Y, Li X, Ren L, Zhao J et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395 (10223): 497-506. doi: 10.1016/S0140- 6736(20)30183-5
Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G et al. (2020). Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology 2 (7): e393-e400. doi: 10.1016/ S2665-9913(20)30164-8
Jia R, Wang X, Liu P, Liang X, Ge Y et al. (2020). Mild cytokine elevation, moderate CD4+T cell response and abundant antibody production in children with COVID-19. Virologica Sinica 35 (6): 734-743. doi: 10.1007/s12250-020-00265-8
Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW et al. (2020). Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. doi: 10.1101/2020.08.12.20169359
Kaplan MJ, Radic M (2012). Neutrophil extracellular traps: doubleedged swords of innate immunity. The Journal of Immunology 189 (6): 2689-2695. doi: 10.4049/jimmunol.1201719
Katz LM (2021). (A Little) Clarity on convalescent plasma for Covid-19. The New England Journal of Medicine 384 (7): 666- 668. doi: 10.1056/NEJMe2035678
Khanmohammadi S, Rezaei N (2021). Role of Toll‐like receptors in the pathogenesis of COVID‐19. Journal of Medical Virology 93 (5): 2735-2739. doi: 10.1002/jmv.26826
Kim JS, Lee JY, Yang JW, Lee KH, Effenberger M et al. (2021). Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 11 (1): 316-329. doi: 10.7150/ thno.49713
King A, Vail A, O’leary C, Hannan C, Brough D et al. (2020). Anakinra in COVID-19: important considerations for clinical trials. The Lancet Rheumatology 2 (7): e379-e381. doi: 10.1016/ S2665-9913(20)30160-0
Kow CS, Hasan SS (2021). Interferon-based therapies in COVID-19. International Immunopharmacology 93: 107415. doi: 10.1016/j.intimp.2021.107415
Kumar V (2020). Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. International Immunopharmacology 89: 107087. doi: 10.1016/j. intimp.2020.107087
Lai W, Wang J, Huang B, Lin EP, Yang P (2019). A novel TNF-αtargeting aptamer for TNF-α-mediated acute lung injury and acute liver failure. Theranostics 9 (6): 1741-1751. doi: 10.7150/ thno.30972
Langer-gould A, Smith JB, Gonzales EG, Castillo RD, Figueroa JG et al. (2020). Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. International Journal of Infectious Diseases 99: 291-297. doi: 10.1016/j. ijid.2020.07.081
Lee KH, Kronbichler A, Park DD, Park Y, Moon H et al. (2017). Neutrophil extracellular traps (NETs) in autoimmune diseases: a comprehensive review. Autoimmunity Reviews 16 (11): 1160-1173. doi: 10.1016/j.autrev.2017.09.012
Lei P, Fan B, Mao J, Wang P (2020). Multiple parameters required for diagnosis of COVID-19 in clinical practice. Journal of Infection 80 (6): e27-e28. doi: 10.1016/j.jinf.2020.03.016
Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A et al. (2021). Early high-titer plasma therapy to prevent severe Covid-19 in older adults. New England Journal of Medicine 384 (7): 610-618. doi: 10.1056/NEJMoa2033700
Loo J, Spittle DA, Newnham M (2021). COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 76 (4): 412-420. doi: 10.1136/ thoraxjnl-2020-216243
Lucherini (2018). Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases. Clinical and Experimental Rheumatology 36 (Suppl. 110): S3- S9.
Luchsinger LL, Hillyer CD (2021). Vaccine efficacy probable against COVID-19 variants. Science 371 (6534): 1116.1-1116. doi: 10.1126/science.abg9461
Mahil SK, Dand N, Mason KJ, Yiu ZZ, Tsakok T et al. (2021). Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study. Journal of Allergy and Clinical Immunology 147 (1): 60-71. doi: 10.1016/j.jaci.2020.10.007
Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS (2020). Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. The Lancet Rheumatology 2 (6): e358-e367. doi: 10.1016/S2665-9913(20)30096-5
Min C, Cheon S, Ha N, Sohn KM, Kim Y et al. (2016). Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Scientific Reports 6 (1). doi: 10.1038/ srep25359
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN et al. (2021). Safety and efficacy of inhaled nebulised interferon beta1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine 9 (2): 196-206. doi: 10.1016/ S2213-2600(20)30511-7
Moradimajd P, Samaee H, Sedigh‐maroufi S, Kourosh‐aami M, Mohsenzadagan M (2021). Administration of intravenous immunoglobulin in the treatment of COVID‐19: a review of available evidence. Journal of Medical Virology 93 (5): 2675- 2682. doi: 10.1002/jmv.26727
Morin L, Savale L, Pham T, Colle R, Figueiredo S et al. (2021). Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 325 (15): 1525. doi: 10.1001/jama.2021.3331
Mousavizadeh L, Ghasemi S (2021). Genotype and phenotype of COVID-19: their roles in pathogenesis. Journal of Microbiology, Immunology and Infection 54 (2): 159-163. doi: 10.1016/j.jmii.2020.03.022
Narain S, Stefanov DG, Chau AS, Weber AG, Marder G et al. (2021). Comparative survival analysis of immunomodulatory therapy for coronavirus disease 2019 cytokine storm. Chest 159 (3): 933-948. doi: 10.1016/j.chest.2020.09.275
Nigrovic PA (2020). COVID-19 cytokine storm: what is in a name? Annals of the Rheumatic Diseases 80 (1): 3-5. doi: 10.1136/ annrheumdis-2020-219448
Paules CI, Marston HD, Fauci AS (2020). Coronavirus infections— more than just the common cold. JAMA 323 (8): 707. doi: 10.1001/jama.2020.0757
Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V et al. (2021). Repurposed antiviral drugs for Covid-19 — interim WHO Solidarity Trial results. New England Journal of Medicine 384 (6): 497-511. doi: 10.1056/NEJMoa2023184
Perego E, Callard F, Stras L, Melville-Johannesson B, Pope R et al. (2020). Why we need to keep using the patient made term “Long Covid.” BMJ Opinion. Published October 1.
Ramos-casals M, Brito-zerón P, Mariette X (2021). Systemic and organ-specific immune-related manifestations of COVID-19. Nature Reviews Rheumatology 17 (6): 315-332. doi: 10.1038/ s41584-021-00608-z
Richardson P, Griffin I, Tucker C, Smith D, Oechsle O et al. (2020). Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet 395 (10223): e30-e31. doi: 10.1016/S0140-6736(20)30304-4
Robinson PC, Liew DF, Liew JW, Monaco C, Richards D et al. (2020). The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19. Med 1 (1): 90-102. doi: 10.1016/j. medj.2020.11.005
Salah HM, Mehta JL (2021). Meta-analysis of the effect of colchicine on mortality and mechanical ventilation in COVID-19. The American Journal of Cardiology 145: 170-172. doi: 10.1016/j. amjcard.2021.02.005
Salama C, Han J, Yau L, Reiss WG, Kramer B et al. (2021). Tocilizumab in patients hospitalized with Covid-19 pneumonia. New England Journal of Medicine 384 (1): 20-30. doi: 10.1056/ NEJMoa2030340
Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS et al. (2020). Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. European Journal of Pharmacology 883: 173375. doi: 10.1016/j.ejphar.2020.173375
Shang L, Zhao J, Hu Y, Du R, Cao B (2020). On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet 395 (10225): 683-684. doi: 10.1016/S0140-6736(20)30361-5
Schnappauf O, Chae JJ, Kastner DL, Aksentijevich I (2019). The pyrin inflammasome in health and disease. Frontiers in Immunology 10. doi: 10.3389/fimmu.2019.01745
Schwartz M (2021). MIS-C: post-infectious syndrome or persistent infection? The Lancet Infectious Diseases 21 (5): e116. doi: 10.1016/S1473-3099(20)30786-6
Seif F, Aazami H, Khoshmirsafa M, Kamali M, Mohsenzadegan M et al. (2020). JAK inhibition as a new treatment strategy for patients with COVID-19. International Archives of Allergy and Immunology 181 (6): 467-475. doi: 10.1159/000508247
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG et al. (2021). A randomized trial of convalescent plasma in Covid-19 severe pneumonia. New England Journal of Medicine 384 (7): 619-629. doi: 10.1056/NEJMoa2031304
Skevaki C, Pararas M, Kostelidou K, Tsakris A, Routsias JG (2015). Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clinical & Experimental Immunology 180 (2): 165-177. doi: 10.1111/cei.12578
Snijder EJ, Van Der Meer Y, Zevenhoven-dobbe J, Onderwater JJM, Van Der Meulen J et al. (2006). Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. Journal of Virology 80 (12): 5927-5940. doi: 10.1128/JVI.02501-05
Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN et al. (2020). Tocilizumab for treatment of mechanically ventilated patients with COVID-19. doi: 10.1101/2020.05.29.20117358
Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I et al. (2020). Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology 39 (7): 2085-2094. doi: 10.1007/s10067-020- 05190-5
Soy M, Atagündüz P, Atagündüz I, Sucak GT (2021). Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatology International 41 (1): 7-18. doi: 10.1007/s00296-020-04636-y
Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O et al. (2020). COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases 20 (4): 400-402. doi: 10.1016/S1473-3099(20)30132-8
Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J et al. (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 324 (13): 1330. doi: 10.1001/jama.2020.17023
Stone JH, Frigault MJ, Serling-boyd NJ, Fernandes AD, Harvey L et al. (2020). Efficacy of tocilizumab in patients hospitalized with Covid-19. New England Journal of Medicine 383 (24): 2333- 2344. doi: 10.1056/NEJMoa2028836
Su S, Wong G, Shi W, Liu J, Lai AC et al. (2016). Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends in Microbiology 24 (6): 490-502. doi: 10.1016/j.tim.2016.03.003
Sun J, He W, Wang L, Lai A, Ji X et al. (2020). COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends in Molecular Medicine 26 (5): 483-495. doi: 10.1016/j. molmed.2020.02.008
Tanaka T, Narazaki M, Kishimoto T (2014). IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology 6 (10): a016295-a016295. doi: 10.1101/cshperspect. a016295
Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT (2012). PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunological Reviews 249 (1): 158-175. doi: 10.1111/j.1600- 065X.2012.01146.x
Tharaux P, Pialoux G, Pavot A, Mariette X, Hermine O et al. (2021). Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNOANA-1): a randomised controlled trial. The Lancet Respiratory Medicine 9 (3): 295-304. doi: 10.1016/S2213-2600(20)30556-7
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG et al. (2020). Effect of dexamethasone on days alive and ventilatorfree in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA 324 (13): 1307. doi: 10.1001/jama.2020.17021
Toniati P, Piva S, Cattalini M, Garrafa E, Regola F et al. (2020). Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews 19 (7): 102568. doi: 10.1016/j. autrev.2020.102568
Tzilas V, Manali E, Papiris S, Bouros D (2020). Intravenous immunoglobulin for the treatment of COVID-19: a promising tool. Respiration 99 (12): 1087-1089. doi: 10.1159/000512727
Veras FP, Pontelli MC, Silva CM, Toller-kawahisa JE, De Lima M et al. (2020). SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology. Journal of Experimental Medicine 217 (12). doi: 10.1084/jem.20201129
Walls AC, Park Y, Tortorici MA, Wall A, Mcguire AT et al. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181 (2): 281-292.e6. doi: 10.1016/j. cell.2020.02.058
Weisberg SP, Connors T, Zhu Y, Baldwin M, Lin W et al. (2020). Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19. medRxiv. doi: 10.1101/2020.07.12.20151068
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C et al. (2020). Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367 (6483): 1260-1263. doi: 10.1126/ science.abb2507
Xie Y, Cao S, Dong H, Li Q, Chen E et al. (2020). Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19. Journal of Infection 81 (2): 318-356. doi: 10.1016/j.jinf.2020.03.044
Xu X, Han M, Li T, Sun W, Wang D et al. (2020). Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences 117 (20): 10970-10975. doi: 10.1073/pnas.2005615117
Yao XH, Li TY, He ZC, Ping YF, Liu HW et al. (2020). A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi = Chinese Journal of Pathology 49 (5): 411-417 (in Chinese). doi: 10.3760/ cma.j.cn112151
Zalinger ZB, Elliott R, Rose KM, Weiss SR (2015). MDA5 is critical to host defense during infection with murine coronavirus. Journal of Virology 89 (24): 12330-12340. doi: 10.1128/JVI.01470-15
Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-velez M et al. (2020a). Inborn errors of type I IFN immunity in patients with lifethreatening COVID-19. Science 370 (6515): eabd4570. doi: 10.1126/science.abd4570
Zhang S, Li L, Shen A, Chen Y, Qi Z (2020b). Rational use of tocilizumab in the treatment of novel coronavirus pneumonia. Clinical Drug Investigation 40 (6): 511-518. doi: 10.1007/ s40261-020-00917-3
Zhou F, Yu T, Du R, Fan G, Liu Y et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 395 (10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3